Li-Fraumeni syndrome synonyms

Li-Fraumeni syndrome (LFS) is officially recognized by this name, though it is historically and clinically referred to as SBLA syndrome, reflecting its association with Sarcoma, Breast, Leukemia, and Adrenal gland cancers. Because it is a hereditary cancer predisposition syndrome, it is also classified in medical literature as a TP53 germline mutation syndrome, highlighting the specific genetic driver of the condition.

Why does Li-Fraumeni syndrome have multiple names?

The naming of Li-Fraumeni syndrome reflects both its clinical history and its genetic understanding. In 1969, physicians Frederick Li and Joseph Fraumeni identified a cluster of families with a high incidence of diverse cancers, leading to the eponym "Li-Fraumeni." Later, as the pattern of malignancies became clearer, it was often called SBLA syndrome to describe the specific tumor types (Sarcoma, Breast, Leukemia, Adrenal). However, as medical science evolved to identify the underlying genetic cause—a mutation in the TP53 tumor suppressor gene—the term TP53 germline mutation syndrome became the preferred clinical descriptor. This transition from descriptive naming (based on symptoms) to molecular naming (based on genetics) is common in modern oncology.

What are the official medical classifications for Li-Fraumeni syndrome?

For the purpose of medical records, insurance coding, and international research, Li-Fraumeni syndrome is categorized under specific identification systems. These codes ensure that clinicians and researchers worldwide are referring to the same condition:

• Orphanet: ORPHA540


• OMIM (Online Mendelian Inheritance in Man): 151623


• ICD-10: D48.9 (Neoplasm of uncertain behavior) or Z80.0 (Family history of malignant neoplasm)


• GARD (Genetic and Rare Diseases Information Center): GARD: 6883

Which name should patients use when communicating with doctors?

While Li-Fraumeni syndrome is the universally accepted name, using the term TP53 germline mutation syndrome is highly effective when speaking with geneticists or oncologists. This is because the clinical management of the condition is centered on the specific TP53 mutation status. If you are reviewing older medical records, you may encounter the term SBLA syndrome, but this is largely considered an outdated historical descriptor. Currently, 53 people in our Li-Fraumeni syndrome community at DiseaseMaps.org have shared their experiences, and most find that referencing the TP53 status alongside the syndrome name helps facilitate the most accurate communication with their care teams.

Are there variations in how Li-Fraumeni syndrome is named globally?

International medical traditions generally standardize on Li-Fraumeni syndrome as the primary name in both English and non-English speaking countries. In some academic contexts, especially in European genetic registries, you may see it referred to as p53-related cancer syndrome. Regardless of the regional variation, the diagnostic criteria remain consistent, focusing on the high-risk, early-onset nature of the cancers associated with the condition.

Next steps

• Consult a board-certified genetic counselor to discuss your specific TP53 variant.


• Request that your medical records use the term Li-Fraumeni syndrome (ICD-10 or equivalent) to ensure accurate cross-specialty communication.


• Connect with the 53 members of our Li-Fraumeni syndrome community at DiseaseMaps.org to share resources and support.


• Ensure your primary care physician is aware of the specific surveillance protocols required for Li-Fraumeni syndrome.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: Li-Fraumeni syndrome (ORPHA540)


• NIH GARD: Genetic and Rare Diseases Information Center - Li-Fraumeni syndrome


• OMIM: Li-Fraumeni Syndrome; LFS (151623)


• Li-Fraumeni Syndrome Association (LFSA): Patient-focused clinical resources